FDA Bursts

In cooperation with the Food and Drug Administration (FDA), and as a service to our Members, we will periodically distribute information about newly approved therapies or significant changes to approved therapies. This helps the FDA to inform professionals in the patient care arena of recent approvals in a timely manner. Included in the email from the FDA is a link to the product label, which will provide the relevant clinical pharmacology information on the indication, contraindications, dosing, and safety. In sending this information, we do not endorse any product or therapy and do not take any position on the safety or efficacy of the product or therapy described.

2021 FDA Bursts

FDA Approves ORGOVYX (relugolix) for the Treatment of Advanced Prostate Cancer

FDA Approves MARGENZA in Adult Patients with Metastatic HER2-Positive Breast Cancer who Have Received Two or More Prior Anti-HER2 Regimens



2020 FDA Bursts

2019 FDA Bursts

2018 FDA Bursts

2017 FDA Bursts

2016 FDA Bursts